A Long-term Follow-up Study of Pulmonary Function Changes Using Phase-resolved Functional Lung MRI in Patients With COVID-19

Status

UNKNOWN

Phases

Unknown

Study type

Observational

Source

ClinicalTrials.gov

Registry ID

NCT05933317

Enrollment

150

Registered

2023-07-06

Start date

2023-01-01

Completion date

2024-12-31

Last updated

2023-07-06

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Pulmonary Function

Brief summary

So far, the number of COVID-19 infections worldwide has exceeded 700 million. Long-term damage to the lungs is a major sequela of COVID infection. Pulmonary function testing is an important means for the evaluation of lung damage. MRI examinations with free breathing and no contrast agent can prevent patients from suffering from ionizing radiation damage caused by multiple CT examinations.

Interventions

DIAGNOSTIC_TESTFunctional lung MRI

Functional lung MRI

Study design

Observational model

COHORT

Time perspective

PROSPECTIVE

Eligibility

Sex/Gender

ALL

Age

18 Years to 90 Years

Healthy volunteers

Yes

Inclusion criteria

* Older than 18 years; Sign the informed consent; Patients diagnosed with COVID-19 by nucleic acid test and survived to be discharged; Complete clinical data during hospitalization.

Exclusion criteria

* Patients with bacterial pneumonia; Patients with MRI contraindications.

Design outcomes

Primary

Measure	Time frame	Description
QDP, VDP	6 months	perfusion defect percentage, ventilation defect percentage

Countries

China

Contacts

Primary ContactTao Ouyang, Dr.

ouyt1996@163.com+86 18720931226

Outcome results

None listed

Source: ClinicalTrials.gov · Data processed: Feb 5, 2026